Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond
Sign Up to like & getrecommendations! Published in 2020 at "NPJ Breast Cancer"
DOI: 10.1038/s41523-020-0153-3
Abstract: Human epidermal growth factor receptor 2–positive (HER2+) breast cancer accounts for ~25% of breast cancer cases. Monoclonal antibodies (mAbs) against HER2 have led to unparalleled clinical benefit for a subset of patients with HER2+ breast… read more here.
Keywords: cancer; immunotherapies her2; her2 breast; breast cancer ... See more keywords